Roivant Sciences Ltd.

NasdaqGS:ROIV Stock Report

Market Cap: US$9.1b

Roivant Sciences Management

Management criteria checks 4/4

Roivant Sciences' CEO is Matt Gline, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is $738.19K, comprised of 98.2% salary and 1.8% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $221.65K. The average tenure of the management team and the board of directors is 3.8 years and 3.2 years respectively.

Key information

Matt Gline

Chief executive officer

US$738.2k

Total compensation

CEO salary percentage98.2%
CEO tenure3.8yrs
CEO ownership0.002%
Management average tenure3.8yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Oct 22

Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position

Aug 22
Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Aug 22

Roivant Sciences: Executing On Huge Buyback Program With More To Come

Jun 02

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Mar 18

We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

Feb 21
We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Nov 15
These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Apr 26
Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Nov 22
Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

Sep 29
Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

CEO Compensation Analysis

How has Matt Gline's remuneration changed compared to Roivant Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$5b

Jun 30 2024n/an/a

US$5b

Mar 31 2024US$738kUS$725k

US$4b

Dec 31 2023n/an/a

US$5b

Sep 30 2023n/an/a

-US$927m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023US$49mUS$725k

-US$1b

Dec 31 2022n/an/a

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$1b

Mar 31 2022US$30mUS$725k

-US$845m

Dec 31 2021n/an/a

-US$1b

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$888m

Mar 31 2021US$8mUS$350k

-US$809m

Compensation vs Market: Matt's total compensation ($USD738.19K) is below average for companies of similar size in the US market ($USD7.74M).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


CEO

Matt Gline (40 yo)

3.8yrs

Tenure

US$738,189

Compensation

Mr. Matthew Gline, also known as Matt, is Chief Executive Officer of Roivant Sciences Ltd. since January 26, 2021 and its Director since September 30, 2021. He has been Chief Executive Officer of Roivant S...


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Gline
CEO & Director3.8yrsUS$738.19k0.0024%
$ 221.6k
Mayukh Sukhatme
President3.8yrsUS$574.56k0.50%
$ 45.8m
Richard Pulik
Chief Financial Officer3.2yrsUS$5.15m0.020%
$ 1.9m
Rakhi Kumar
Chief Accounting Officer6.3yrsUS$4.33m0.016%
$ 1.4m
Eric Venker
President & COO6yrsUS$48.49m0.038%
$ 3.4m
Drew Kramer
Chief Information Officerno datano datano data
Josh Chen
General Counselno datano datano data
Kelly Graff
Head of People2.8yrsno datano data
Alex Gasner
Executive Vice President of Roivant Healthno datano datano data
Matt Maisak
Chief Operating Officer of Roivant Platformsno datano datano data
Srini Ramanathan
Chief Development Officer2.5yrsno datano data
David Rubenstein
Chief Scientific Officer of Dermavantno datano datano data

3.8yrs

Average Tenure

44yo

Average Age

Experienced Management: ROIV's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthew Gline
CEO & Director3.2yrsUS$738.19k0.0024%
$ 221.6k
Mayukh Sukhatme
Presidentless than a yearUS$574.56k0.50%
$ 45.8m
Meghan FitzGerald
Independent Director1.7yrsUS$941.68k0.0018%
$ 162.4k
Keith Manchester
Independent Director10.8yrsUS$442.59k0.17%
$ 15.8m
James Momtazee
Independent Director3.2yrsUS$459.24k0.011%
$ 967.8k
Daniel Gold
Independent Director4.8yrsUS$449.24k0.88%
$ 80.6m
Melissa Epperly
Independent Director2.4yrsUS$444.24k0.0030%
$ 270.9k
Ilan Oren
Independent Chairman10.8yrsUS$488.49k0.011%
$ 1.0m

3.2yrs

Average Tenure

50yo

Average Age

Experienced Board: ROIV's board of directors are considered experienced (3.2 years average tenure).